Research programme: anti-infectious disease MicroRNAs - Novartis
Latest Information Update: 01 Jul 2025
At a glance
- Originator Regulus Therapeutics
- Developer Novartis
- Class Anti-infectives; MicroRNAs
- Mechanism of Action MicroRNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Infections
Most Recent Events
- 25 Jun 2025 Regulus Therapeutics has been acquired and merged into Novartis
- 31 Dec 2021 Early research in Infections in USA (unspecified route) (Regulus Therapeutics pipeline, December 2021)